{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Renal+Cell+Carcinoma+%28+mRCC%29&page=2",
    "query": {
      "condition": "Metastatic Renal Cell Carcinoma ( mRCC)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Renal+Cell+Carcinoma+%28+mRCC%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T09:51:25.537Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01224288",
      "title": "Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Perfusion CT scan",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2011-01-05",
      "completion_date": "2029-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-07-24T09:51:25.537Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01224288"
    },
    {
      "nct_id": "NCT05479812",
      "title": "Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Solid Tumor",
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "WTX-124",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Werewolf Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2022-05-20",
      "completion_date": "2026-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-09",
      "last_synced_at": "2026-07-24T09:51:25.537Z",
      "location_count": 14,
      "location_summary": "Scottsdale, Arizona • Tampa, Florida • Atlanta, Georgia + 11 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05479812"
    },
    {
      "nct_id": "NCT01767636",
      "title": "Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma of the Collecting Ducts of Bellini",
        "Chromophobe Renal Cell Carcinoma",
        "Kidney Medullary Carcinoma",
        "Kidney Oncocytoma",
        "Metastatic Renal Cell Cancer",
        "Papillary Renal Cell Carcinoma",
        "Recurrent Renal Cell Carcinoma",
        "Sarcomatoid Renal Cell Carcinoma",
        "Stage IV Renal Cell Cancer"
      ],
      "interventions": [
        {
          "name": "Pazopanib Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2013-05-16",
      "completion_date": "2021-01-20",
      "has_results": true,
      "last_update_posted_date": "2025-03-03",
      "last_synced_at": "2026-07-24T09:51:25.537Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01767636"
    },
    {
      "nct_id": "NCT07578025",
      "title": "Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Clear Cell Renal Cell Carcinoma",
        "Stage IV Renal Cell Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "C. butyricum CBM 588 Probiotic Strain Capsule Formulation MO-03",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Zanzalintinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2026-11-28",
      "completion_date": "2028-06-24",
      "has_results": false,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-07-24T09:51:25.537Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07578025"
    },
    {
      "nct_id": "NCT04508725",
      "title": "Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Kidney Cancer",
        "Renal Cell Carcinoma",
        "Metastatic Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Doppler Ultrasound",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "SIEMENS S3000 and Verasonics Vantage 256",
          "type": "DEVICE"
        },
        {
          "name": "Standard-of-care Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI)",
          "type": "DRUG"
        },
        {
          "name": "Standard-of-care non-immune checkpoint inhibitor (ICI) such as single-agent VEGFR2 TKI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2020-12-05",
      "completion_date": "2023-11-30",
      "has_results": true,
      "last_update_posted_date": "2025-07-25",
      "last_synced_at": "2026-07-24T09:51:25.537Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04508725"
    },
    {
      "nct_id": "NCT03200587",
      "title": "Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Avelumab",
          "type": "DRUG"
        },
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2018-06-21",
      "completion_date": "2021-11-25",
      "has_results": false,
      "last_update_posted_date": "2024-07-03",
      "last_synced_at": "2026-07-24T09:51:25.537Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03200587"
    },
    {
      "nct_id": "NCT07227415",
      "title": "Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Renal Cell",
        "Advanced Renal Cell Carcinoma",
        "Renal Cancer",
        "Renal Neoplasm",
        "Clear Cell Renal Cell Carcinoma",
        "Metastatic Renal Cell Carcinoma",
        "Clear-cell Metastatic Renal Cell Carcinoma",
        "Carcinoma, Renal Cell Metastasis",
        "Advanced or Metastatic Renal Cell Carcinoma",
        "Carcinoma, Renal Cell, Advanced",
        "Metastatic Renal Cell Cancer",
        "Metastatic Renal Cell Carcinoma ( mRCC)",
        "Metastatic/Advanced Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "PF-08634404",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Axitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 224,
      "start_date": "2026-02-10",
      "completion_date": "2028-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-07-24T09:51:25.537Z",
      "location_count": 109,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 70 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07227415"
    },
    {
      "nct_id": "NCT00556049",
      "title": "Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Renal Cell Carcinoma",
        "Neoplasm Metastases"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Sunitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2007-12",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2016-04-21",
      "last_synced_at": "2026-07-24T09:51:25.537Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00556049"
    },
    {
      "nct_id": "NCT07188896",
      "title": "A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Renal Cell Carcinoma (aRCC)",
        "Metastatic Renal Cell Carcinoma ( mRCC)",
        "Clear Cell Renal Cell Carcinoma (ccRCC)"
      ],
      "interventions": [
        {
          "name": "Fianlimab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brian Rini",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2026-04-29",
      "completion_date": "2030-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-07-24T09:51:25.537Z",
      "location_count": 2,
      "location_summary": "Nashville, Tennessee • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07188896"
    },
    {
      "nct_id": "NCT04919122",
      "title": "Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Metastatic Renal Cell Carcinoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 468,
      "start_date": "2022-04-01",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-11",
      "last_synced_at": "2026-07-24T09:51:25.537Z",
      "location_count": 14,
      "location_summary": "Iowa City, Iowa • Kansas City, Kansas • New Orleans, Louisiana + 11 more",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04919122"
    }
  ]
}